Related Experiment Video
Updated: Apr 5, 2026
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
16.7K
CXCR4 and Glioblastoma
1Proximagen Ltd, Building 250, Babraham Research Campus, Babraham Cambridge CB223AT, UK. peter.richardson@proximagen.com.
Anti-Cancer Agents in Medicinal Chemistry
|August 25, 2015
Summary
CXCR4 antagonists show promise for treating glioblastoma by targeting cancer stem cells. Blocking the CXCR4 receptor (C-X-C chemokine receptor type 4) may inhibit tumor growth and improve treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Neuroscience
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
- Cancer stem cells (CSCs) drive GBM growth, recurrence, and treatment resistance.
- The chemokine receptor CXCR4 and its ligand SDF-1 (CXCL12) are implicated in GBM pathogenesis.
Purpose of the Study:
- To review the therapeutic potential of CXCR4 antagonists for glioblastoma treatment.
- To highlight the role of CXCR4 in glioblastoma stem cell maintenance and tumor biology.
Main Methods:
- Literature review and synthesis of existing research on CXCR4 in glioblastoma.
- Analysis of the role of CXCR4 in cancer stem cell biology, tumor microenvironment, and treatment resistance.
Main Results:
- CXCR4 expression is maintained by GBM driver mutations and positive feedback loops.
- CXCR4 signaling is crucial for glioblastoma cancer stem cell self-renewal and niche maintenance.
- CXCR4 antagonism may overcome resistance to radio- and chemotherapy and inhibit tumor cell migration and angiogenesis.
Conclusions:
- CXCR4 antagonists represent a promising therapeutic strategy for glioblastoma.
- Targeting CXCR4 could disrupt key pathways driving glioblastoma progression and stemness.
